01 febbraio 2021 13:08
Fonte: Adnkronos
#economia-e-finanza
SAN MATEO, Calif., Feb. 1, 2021 /PRNewswire/ Phoenix Venture Partners LLC (PVP) announced today that it officially closed its latest flagship venture capital fund, PVP III LP at EOY 2020. The Fund was oversubscribed and its limited partners (both returning and new) are composed of sophisticated financial institutions, family offices, and leading multinational corporations (strategic investors). PVP III LP s strategic investors include a who s who of market leaders around the world in their respective industries, including Pfizer Inc. (NYSE: PFE), Corning Incorporated (NYSE:GLW), W. L. Gore & Associates, Showa Denko K. K. (TYO:4004), Nissan Chemical Corporation (TYO:4021), Nagase & Co., Ltd. (TYO:8012), and LG Technology Ventures, which is the investment vehicle of LG Chem, Ltd. (KRX: 051910).
To embed, copy and paste the code into your website or blog:
The European Court of Justice has confirmed that financial investors can incur parental liability for the anticompetitive practices of portfolio companies, even after an IPO that left the investor holding only a minority stake in the company, provided that they still have sufficient representation at the board of directors. This judgment is of major interest to private equity funds and other financial investors, demonstrating the need to balance their desire to closely oversee the portfolio companies’ strategies with the risk of being found liable for any anticompetitive practices implemented at a lower level in these companies.
Share this article
Share this article
TEL AVIV, Israel, Jan. 27, 2021 /PRNewswire/ The seed investment round of $2.2M was led by Israeli early-stage deep tech fund VentureIsrael, with participation of private investors from Israel and Singapore. The funding will be used to accelerate from pilot projects to full deployment of the Cydome solution among key customers and partners.
VentureIsrael invests in Israeli startup Cydome, the world leading maritime cyber security solution
developed a cyber security solution seamlessly safeguarding the maritime and naval IoT ecosystem, including guidance, sensor, control, command, communication systems and linkage to coastal infrastructures; providing end-to-end protection from the kernel level using data and network isolation; rapid, reliable and automatic threat detection and protection.
VentureIsrael Invests in Israeli Startup QuantLR, Developer of the World s Most Cost Affordable Quantum Cryptography Solution
USA - English
News provided by
Share this article
Share this article
TEL AVIV, Israel, Jan. 19, 2021 /PRNewswire/ An Israeli deep tech fund VentureIsrael participated in the investment round alongside with the world s largest equity crowdfunding platform OurCrowd, as well as Jerusalem s early-stage fund and incubator Labs/02. The investments will be used to continue R&D, as well as to begin commercialization of the QuantLR s technology.
VentureIsrael invests in Israeli startup QuantLR, developer of the world’s most cost affordable Quantum Cryptography solution
QuantLR has developed a secure most cost affordable Quantum Cryptography solution using the principles of quantum physics to protect the world s most sensitive data. QuantLR successfully deployed a proof of concept showing that its Quantum Key Distribution solution is ready for mass deployment
AltPep Raises $23M Jumpstarting Work on Alzheimer s Disease
Search jobs SEATTLE - January 14, 2021 - (Newswire.com)
AltPep Corporation, a privately held biomedical company focused on diagnosing and treating Central Nervous System amyloid disorders, starting with Alzheimer s Disease, today announced it closed a $23.150 million Series A investment round. Matrix Capital Management led the investment, with significant participation by Alexandria Venture Investments. In conjunction with the financing, David Goel, Managing General Partner and Founder of Matrix Capital Management and Joel Marcus, Executive Chairman and Founder of Alexandria Real Estate Equities/Alexandria Venture Investments, have joined the AltPep Board of Directors.
The proceeds of the Series A investment will be used to advance a breakthrough technology developed at the University of Washington laboratory of AltPep Founder and CEO, Valerie Daggett, Ph.D., that targets the misfolded forms of amyloi